A groundbreaking study originating from a collaborative effort between the University of Sydney, the Baird Institute for Applied Heart and Lung Research, and Royal Prince Alfred Hospital in Sydney has fundamentally challenged a long-standing tenet of cardiovascular biology. The investigation, which produced findings subsequently published in the esteemed journal Circulation Research, presents compelling evidence that the adult human heart possesses an inherent, albeit limited, ability to generate new muscle cells following an ischemic event such as a heart attack. This revelation significantly departs from the previously held medical consensus that myocardial tissue lost due to injury is irrevocably damaged and incapable of functional restoration, opening promising new avenues for the development of innovative therapeutic strategies aimed at mitigating the devastating consequences of heart disease.
For decades, the prevailing understanding within cardiology was that once cardiac muscle cells, known as cardiomyocytes, were destroyed during a myocardial infarction, they were replaced by inert scar tissue. This fibrotic scar, while essential for maintaining structural integrity and preventing ventricular rupture in the immediate aftermath of an attack, does not contract or contribute to the heart’s pumping function. Consequently, the affected region of the heart becomes permanently compromised, leading to a diminished capacity to circulate blood efficiently throughout the body. This impaired function often progresses to heart failure, a chronic and debilitating condition where the heart struggles to meet the metabolic demands of vital organs. The conventional wisdom posited that adult mammalian hearts, unlike those of certain lower vertebrates or even neonatal mammals, had lost their regenerative potential early in development, rendering any damage irreversible.
The global burden of cardiovascular disease underscores the profound implications of this new discovery. It remains the foremost cause of mortality worldwide, accounting for millions of deaths annually. In Australia, for instance, nearly a quarter of all fatalities are attributed to cardiovascular ailments. A heart attack, specifically, can obliterate up to one-third of the heart’s contractile cells. While advancements in acute care and intervention have dramatically improved survival rates over the past decade, merely surviving the initial event does not guarantee a full recovery or freedom from long-term complications. A significant proportion of survivors eventually develop heart failure, a condition characterized by a progressive decline in the heart’s pumping efficacy. The current definitive treatment for end-stage heart failure is a heart transplant, a life-saving but profoundly limited option. The scarcity of donor organs is a critical constraint; in Australia, for example, approximately 144,000 individuals live with heart failure, yet only around 115 heart transplants are performed each year. This stark disparity highlights an urgent and unmet medical need for novel therapeutic approaches that can address the root cause of post-infarction damage.
Dr. Robert Hume, the lead author of the study from the Faculty of Medicine and Health and the Charles Perkins Centre, who also heads Translational Research at the Baird Institute, elucidated the profound significance of these findings. "Historically, we operated under the assumption that when heart cells perished following a heart attack, the affected regions were beyond repair, resulting in a permanently weakened heart less capable of supplying adequate blood to the body’s vital systems," Dr. Hume explained. "Our investigation, however, demonstrates that while scar tissue invariably forms after a myocardial infarction, the heart concurrently initiates the production of new muscle cells, thus opening unforeseen avenues for therapeutic intervention." He further cautioned that while this newfound capacity for muscle cell regrowth is an exciting development, its natural extent is currently insufficient to counteract the devastating functional impairment caused by a heart attack. The overarching objective, therefore, is to leverage this inherent biological mechanism to engineer therapies that can significantly amplify the heart’s natural regenerative capabilities, ultimately aiming to restore myocardial function and prevent or reverse heart failure.
Previous research, predominantly conducted in animal models, particularly mice, had indicated an increase in cellular division, or mitosis, within the heart muscle following an induced myocardial infarction. Mitosis is the fundamental biological process by which a single parent cell divides into two identical daughter cells, enabling growth and tissue repair. However, replicating these observations in adult human cardiac tissue remained an elusive goal, largely due to challenges in obtaining viable and representative samples. This new Australian study marks a pivotal moment as it represents the first conclusive demonstration of this regenerative phenomenon occurring in human hearts, bridging a critical gap between animal research and human physiology.
A distinctive and crucial aspect of this research was the pioneering methodology employed for tissue acquisition. The study relied on a world-first approach that utilized living heart tissue samples collected directly from consenting patients undergoing cardiac bypass surgery at Royal Prince Alfred Hospital in Sydney. These "pre-mortem" samples were harvested from both diseased and non-diseased regions of the same heart. This innovative sampling technique was meticulously developed by Professor Paul Bannon and Professor Sean Lal, who hold joint appointments at the University of Sydney, Royal Prince Alfred Hospital, and The Baird Institute. The ability to analyze metabolically active, living human cardiac tissue provides an unparalleled research tool. Unlike post-mortem samples, which undergo degradation, or animal models, which may not perfectly recapitulate human pathophysiology, these living samples offer a laboratory model that more accurately mirrors the intricate biological processes occurring within a patient’s heart. This enhanced physiological relevance is critical for developing therapies that are truly translatable to clinical practice.
Professor Sean Lal, a senior author of the study from the School of Medical Sciences and a practicing heart failure cardiologist at Royal Prince Alfred Hospital, emphasized the future trajectory of their work. "Our ultimate aspiration is to harness this discovery to generate new heart cells that can effectively reverse the progression of heart failure," Professor Lal stated. "By employing living human heart tissue models in our investigations, we anticipate acquiring more precise and reliable data, which is indispensable for the successful development of novel therapies for cardiac disease." He further highlighted a promising early outcome: their research, utilizing these unique human samples, has already identified several proteins previously implicated in cardiac regeneration within mouse models. The prospect of validating these findings and translating them into human therapeutic strategies is exceptionally encouraging.
The identification of specific proteins involved in this nascent human regenerative process provides critical molecular targets for future research. These proteins could serve as key regulators, offering researchers invaluable clues on how to pharmacologically or genetically stimulate damaged human hearts to produce a greater number of new, functional muscle cells. While the journey from basic discovery to clinically approved treatments is invariably long and complex, requiring extensive further research, rigorous testing, and clinical trials, this foundational discovery provides direct and undeniable evidence that the adult human heart is not an entirely static organ in the face of injury. It possesses an intrinsic, albeit currently insufficient, capacity to repair itself by generating new muscle. This insight injects renewed optimism into the field of regenerative cardiology, holding the promise of a future where heart failure could be not just managed, but potentially reversed, transforming the lives of millions worldwide.
About the Author
